Fiche centre
Columbia University Medical Center
New York — United States
Essais liés38clinical trials
VilleNew Yorklocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07164443
Essais cliniques associés
38| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| BIA 28-6156 10 mg | Parkinson | Phase 2 | NCT05819359 | ACTIVATE — Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD | COMPLETED |
| EXCOR Active Driving System for Pediatric VAD | Insuffisance cardiaque | Non applicable | NCT05610787 | EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study | ENROLLING_BY_INVITATION |
| FARAPULSE™ Pulsed Field Ablation System | Maladie coronarienne | À vérifier | NCT06431815 | ADVENTPAS — ADVENT Post Approval Study | ACTIVE_NOT_RECRUITING |
| Tofersen | Sclérose latérale amyotrophique | Phase 3 | NCT04856982 | ATLAS — Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | ACTIVE_NOT_RECRUITING |
| CLN-978 | Lupus | Phase 1 | NCT06613360 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus | RECRUITING |
| WATCHMAN FLX LAAC Device | Accident vasculaire cérébral | Non applicable | NCT04394546 | CHAMPION-AF Clinical Trial | ACTIVE_NOT_RECRUITING |
| AFSW Guided DOAC | Accident vasculaire cérébral | Phase 3 | NCT05836987 | REACT-AF — The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | RECRUITING |
| ONC206 | Cancer | Phase 2 | NCT07282587 | Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma | RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT02637856 | A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) | COMPLETED |
| Pasritamig | Cancer | Phase 3 | NCT07164443 | KLK2-comPAS — A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING |
| TAK-935 | Épilepsie | Phase 2 | NCT03650452 | ELEKTRA — A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies | COMPLETED |
| Sonrotoclax | Cancer | Phase 3 | NCT07277231 | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia | RECRUITING |
| Photodynamic therapy-Photofrin | Cancer | Phase 3 | NCT02082522 | Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS) | TERMINATED |
| Tacabrutideg | Cancer | Phase 1/2 | NCT05006716 | CaDAnCe-101 — A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | RECRUITING |
| Soticlestat | Épilepsie | Phase 2 | NCT03694275 | A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY) | COMPLETED |
| Ocrelizumab | SEP | Phase 1 | NCT03972306 | A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis | COMPLETED |
| Amivantamab | Cancer | Phase 3 | NCT04538664 | PAPILLON — A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions | ACTIVE_NOT_RECRUITING |
| Obinutuzumab | Lupus | Phase 3 | NCT04221477 | REGENCY — A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis | ACTIVE_NOT_RECRUITING |
| Solanezumab | Alzheimer | Phase 3 | NCT02008357 | A4 — Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss | COMPLETED |
| PROVIDUS — A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy | Myopathies | À vérifier | NCT07127978 | PROVIDUS — A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy | RECRUITING |
| Cenerimod | Lupus | Phase 3 | NCT05672576 | OPUS-2 — A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING |
| Acoramidis | Alzheimer | Phase 3 | NCT06563895 | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | RECRUITING |
| Autoimmune Features of Neurodegenerative Disorders | Alzheimer | À vérifier | NCT04239079 | Autoimmune Features of Neurodegenerative Disorders | RECRUITING |
| Prasinezumab | Parkinson | Phase 3 | NCT07174310 | PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | RECRUITING |
| TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | SEP | Non applicable | NCT03500328 | TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | ACTIVE_NOT_RECRUITING |
| Tazbentetol | Sclérose latérale amyotrophique | À vérifier | NCT07088159 | Intermediate-size Patient Population Expanded Access Protocol | AVAILABLE |
| ION363 | Sclérose latérale amyotrophique | Phase 3 | NCT04768972 | FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS) | ACTIVE_NOT_RECRUITING |
| RGX-202 | Myopathies | Phase 2/3 | NCT05693142 | AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) | ACTIVE_NOT_RECRUITING |
| Inebilizumab | Lupus | Phase 2 | NCT06570798 | A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases | RECRUITING |
| Litifilimab | Lupus | Phase 2/3 | NCT05531565 | AMETHYST — A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING |
| Actual device PFO closure | Migraine | Non applicable | NCT04100135 | RELIEF — GORE® CARDIOFORM Septal Occluder Migraine Clinical Study | TERMINATED |
| CT1812 | Alzheimer | Phase 2 | NCT05531656 | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| extended release metformin | Alzheimer | Phase 2/3 | NCT04098666 | MAP — Metformin in Alzheimer's Dementia Prevention | ACTIVE_NOT_RECRUITING |
| Hearing Intervention | Alzheimer | Non applicable | NCT06174038 | Early Age-Related Hearing Loss Investigation (EARHLI) | RECRUITING |
| Flow Detection System | Migraine | Phase 3 | NCT01773252 | PFO Detection — Right to Left Cardiac Shunt Detection | TERMINATED |
| Ticagrelor 90 mg twice per day | Migraine | Phase 4 | NCT02518464 | TRACTOR — Ticagrelor Therapy for RefrACTORy Migraine Study | COMPLETED |
| Fenebrutinib | SEP | Phase 3 | NCT04544449 | FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| IGIV-C | Myasthénie | Phase 2 | NCT02473965 | Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis | COMPLETED |